Nicotinamide adenine dinucleotide (nad) metabolism as a relevant target in cancer

HIGHLIGHTS

• who: Lola E. Navas and Amancio Carnero from the Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Rocu00edo, Universidad de Sevilla, Consejo Superior de Investigaciones Cientu00edficas, Sevilla, Spain have published the paper: Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer, in the Journal: Cells 2022, 11, 2627. of /2022/
• what: This trial evaluated the clinical efficacy of the drug in monotherapy and in combination with niacin (vitamin B3) to palliate the toxic effects and in combination with nivolumab, a monoclonal antibody directed at PD1 (programmed death receptor of T lymphocytes . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.